The WIP1 Oncogene Promotes Progression and Invasion of Aggressive Medulloblastoma Variants
暂无分享,去创建一个
Stefan M. Pfister | Paul A. Northcott | Marcel Kool | M. Kool | P. Northcott | S. Pfister | M. Remke | Michael D. Taylor | K. Gandhi | R. Castellino | M. Schniederjan | Marc Remke | Khanjan Gandhi | Robert C. Castellino | Meghan C. Buss | Juhyun Lee | Matthew J. Schniederjan | M. C. Buss | Juhyun Lee | Khanjan Gandhi
[1] Jill P. Mesirov,et al. MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.
[2] G. Reifenberger,et al. Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. , 2010, Cancer research.
[3] D. Ellison,et al. Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis , 2006, Cell cycle.
[4] L. Donehower,et al. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. , 2005, Genes & development.
[5] M. Protopopova,et al. Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.
[6] L. Donehower,et al. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice , 2006, Molecular carcinogenesis.
[7] K. Lindsley. Surveillance scanning of children with medulloblastoma. , 1994, The New England journal of medicine.
[8] S. Scherer,et al. Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma , 2012, Nature.
[9] Hendrik Witt,et al. Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Pietsch,et al. p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease , 2011, Journal of Neuro-Oncology.
[11] N. Onishi,et al. Intrinsic Kinase Activity and SQ/TQ Domain of Chk2 Kinase as Well as N-terminal Domain of Wip1 Phosphatase Are Required for Regulation of Chk2 by Wip1* , 2006, Journal of Biological Chemistry.
[12] E. Appella,et al. Genetic variants and mutations of PPM1D control the response to DNA damage , 2013, Cell cycle.
[13] E. Appella,et al. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis , 2007, Oncogene.
[14] Axel Benner,et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] B. Hinkes,et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. , 2009, European journal of cancer.
[16] Yi Sun,et al. Targeting p53 for Novel Anticancer Therapy. , 2010, Translational oncology.
[17] Shaomeng Wang,et al. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.
[18] S. Croul,et al. Adult medulloblastoma comprises three major molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Curran,et al. A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study (PBTC 25). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Fiscella,et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[21] Peter Donnelly,et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer , 2012, Nature.
[22] E. Appella,et al. Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. , 2007, Cell stem cell.
[23] J. Gutkind,et al. G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.
[24] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.
[25] E. Appella,et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. , 2006, Molecular cell.
[26] N. Onishi,et al. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase , 2006, Cell Death and Differentiation.
[27] S. Donaldson,et al. Medulloblastoma: freedom from relapse longer than 8 years--a therapeutic cure? , 1991, Journal of neurosurgery.
[28] J. Benovic,et al. G protein-coupled receptor kinase 5 phosphorylation of hip regulates internalization of the chemokine receptor CXCR4. , 2011, Biochemistry.
[29] P. Northcott,et al. Functional genomics identifies drivers of medulloblastoma dissemination. , 2012, Cancer research.
[30] S. Pfister. Medulloblastoma: a potpourri of distinct entities , 2012, Acta Neuropathologica.
[31] C. Rudin,et al. Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma , 2009, Science.
[32] M. Scott,et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. , 1997, Science.
[33] T. Merchant,et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.
[34] E. D. de Vries,et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. , 2013, European journal of cancer.
[35] D. Ellison,et al. Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients , 2004, Clinical Cancer Research.
[36] Roger E. Taylor,et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[38] S. Mundell,et al. Trafficking of the HIV Coreceptor CXCR4 , 1999, The Journal of Biological Chemistry.
[39] Masaaki Adachi,et al. p53‐inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK‐p53 signaling in response to UV radiation , 2000, The EMBO journal.
[40] Axel Benner,et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Axel Benner,et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Xiongbin Lu,et al. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. , 2007, Cancer cell.
[43] P. Northcott,et al. CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. , 2012, Cancer research.
[44] Jeffrey R. Marks,et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23 , 2002, Nature Genetics.
[45] Albert J. Fornace,et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.
[46] L. Clegg,et al. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. , 2002, Medical and pediatric oncology.
[47] K. Gandhi,et al. HDM2 promotes WIP1-mediated medulloblastoma growth. , 2012, Neuro-oncology.
[48] J. Benovic,et al. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. , 1998, Annual review of pharmacology and toxicology.
[49] Lawrence A. Donehower,et al. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D , 2007, Journal of Neuro-Oncology.
[50] Arie Perry,et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.
[51] J. Bartek,et al. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint , 2013, The Journal of cell biology.
[52] L. Borgognoni,et al. WIP1 phosphatase modulates the Hedgehog signaling by enhancing GLI1 function , 2013, Oncogene.
[53] G. Rao,et al. c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. , 2003, Neoplasia.
[54] Andrew L Kung,et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[55] Mark L. Greenberg,et al. Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] C. Marras,et al. Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas , 2006, Cancer biology & therapy.
[57] Akira Nakagawara,et al. PPM1D is a potential target for 17q gain in neuroblastoma. , 2003, Cancer research.
[58] J. Biegel,et al. Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients , 2005, Clinical Cancer Research.
[59] N. Warrington,et al. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. , 2005, Cancer research.
[60] R. Klein,et al. SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. , 2001, Development.
[61] J. Mesirov,et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] Steven J. M. Jones,et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.
[63] Dirk Troost,et al. Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.
[64] X. Bian,et al. PREFERENTIAL EXPRESSION OF CHEMOKINE RECEPTOR CXCR4 BY HIGHLY MALIGNANT HUMAN GLIOMAS AND ITS ASSOCIATION WITH POOR PATIENT SURVIVAL , 2007, Neurosurgery.
[65] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.
[66] X. Bian,et al. Preferential Expression of Chemokine Receptor CXCR4 by Highly Malignant Human Gliomas and Its Association with Poor Patient Survival. , 2008, Neurosurgery.
[67] John Y. H. Kim,et al. Overexpressed TP73 induces apoptosis in medulloblastoma , 2007, BMC Cancer.
[68] G. Riggins,et al. c-Myc promoter activation in medulloblastoma. , 2003, Cancer research.